Philadelphia, PA, United States of America

Mario Cesar Rico

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Temple University. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mario Cesar Rico

Introduction

Mario Cesar Rico is an accomplished inventor based in Philadelphia, PA. He has made significant contributions to the field of medicine, particularly in the treatment of liver diseases. His innovative work has led to the development of a unique compound aimed at addressing serious health issues.

Latest Patents

Mario Cesar Rico holds a patent for (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL). This compound is designed for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis, and steatosis. His patent represents a crucial advancement in the fight against liver-related health conditions. He has 1 patent to his name.

Career Highlights

Rico is affiliated with Temple University, where he conducts research and develops innovative solutions for complex medical challenges. His work at the university has positioned him as a key figure in the academic and medical communities.

Collaborations

One of his notable collaborators is Salim Merali. Together, they have worked on various projects aimed at enhancing the understanding and treatment of liver diseases.

Conclusion

Mario Cesar Rico's contributions to medical innovation are noteworthy, particularly in the realm of liver health. His patent for (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) showcases his commitment to improving patient outcomes. His work continues to inspire advancements in medical research and treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…